PT KIMIA FARMA TBK |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 735 IDR | -1.34% |
|
+0.68% | -49.13% |
| 2023 | PT Kimia Farma Tbk Reports Earnings Results for the Nine Months Ended September 30, 2023 | CI |
| 2023 | PT Kimia Farma Tbk Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
| Sales 2021 | 12,858B 797M 66.17B | Sales 2022 | 9,606B 596M 49.43B | Capitalization | 6,026B 374M 31.01B |
|---|---|---|---|---|---|
| Net income 2021 | 302B 18.74M 1.56B | Net income 2022 | -170B -10.54M -875M | EV / Sales 2021 | 1.62 x |
| Net Debt 2021 | 7,275B 451M 37.44B | Net Debt 2022 | 5,960B 370M 30.67B | EV / Sales 2022 | 1.25 x |
| P/E ratio 2021 |
44.6
x | P/E ratio 2022 |
-35.4
x | Employees | 11,560 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 9.96% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.34% | ||
| 1 week | +0.68% | ||
| Current month | -19.23% | ||
| 1 month | -20.11% | ||
| 3 months | -19.67% | ||
| 6 months | +0.68% | ||
| Current year | -49.13% |
1 week
730.00
790.00
1 month
725.00965.00
Current year
700.001 500.00
1 year
685.001 935.00
3 years
685.003 670.00
5 years
540.007 575.00
10 years
540.007 575.00
| Managers | Title | Age | Since |
|---|---|---|---|
David Utama
CEO | Chief Executive Officer | - | 11/22/11 |
Lina Sari
DFI | Director of Finance/CFO | 58 | 28/21/28 |
| Chief Tech/Sci/R&D Officer | 46 | 01/21/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Fahmi Idris
CHM | Chairman | 81 | 14/22/14 |
Dwi Ary Purnomo
BRD | Director/Board Member | 49 | 28/21/28 |
Musthofa Fauzi
BRD | Director/Board Member | 66 | 29/20/29 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 735 | -1.34% | 360,500 |
| 25/24/25 | 745 | -1.32% | 819,700 |
| 24/24/24 | 755 | -0.66% | 593,200 |
| 23/24/23 | 760 | +2.01% | 1,857,100 |
| 22/24/22 | 745 | +2.05% | 1,324,800 |
End-of-day quote INDONESIA S.E., April 26, 2024
More quotes
PT Kimia Farma Tbk is an Indonesia-based company, which is engaged in producing, distributing, and marketing chemical industry product, active pharmaceutical ingredients (API) and high function chemicals (HFC). Its segments include Manufacturing, Distribution, Retail, and Other. The Manufacturing segment includes chemical and pharmaceutical manufacturing, research and development, and manufacturing marketing and marketing of quinine and essential oils; manufacturing and marketing of active pharmaceutical ingredients and HFC, and manufacturing and marketing of pharmaceutical products. The distribution segment is engaged in distribution of pharmaceutical products to domestic market and to the international market, including Saudi Arabia, the United States, Netherlands, the United Kingdom, China, Malaysia, and several other countries. The Retail segment is engaged in the sale of medicines and pharmaceutical products directly to customers.
Sector
Drug Retailers
Calendar
01/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -49.13% | 252M | |
| -32.21% | 15.27B | |
| -31.97% | 10.84B | |
| -30.42% | 6.06B | |
| +8.14% | 6.04B | |
| -11.41% | 5.86B | |
| -0.88% | 4.71B | |
| +52.19% | 4.29B | |
| -12.31% | 3.61B | |
| -14.86% | 3.33B |
- Stock Market
- Equities
- KAEF Stock
